Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

Helen M. Colhoun; Jennifer G. Robinson; Michel Farnier; Bertrand Cariou; Dirk Blom; Dean J. Kereiakes; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari

doi:10.1186/1471-2261-14-121

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

Helen M. Colhoun (Lead / Corresponding author), Jennifer G. Robinson, Michel Farnier, Bertrand Cariou, Dirk Blom, Dean J. Kereiakes, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari

Research output: Contribution to journal › Article › peer-review

49 Citations (Scopus)

Abstract

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PCSK9) under investigation for treatment of hypercholesterolemia and reduction of cardiovascular events.

Original language	English
Pages (from-to)	121
Journal	BMC Cardiovascular Disorders
Volume	14
Issue number	1
DOIs	https://doi.org/10.1186/1471-2261-14-121
Publication status	Published - 2014

Access to Document

10.1186/1471-2261-14-121

Fingerprint

Dive into the research topics of 'Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials'. Together they form a unique fingerprint.

Cite this

Colhoun, H. M., Robinson, J. G., Farnier, M., Cariou, B., Blom, D., Kereiakes, D. J., Lorenzato, C., Pordy, R., & Chaudhari, U. (2014). Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovascular Disorders, 14(1), 121. https://doi.org/10.1186/1471-2261-14-121

Colhoun, Helen M. ; Robinson, Jennifer G. ; Farnier, Michel et al. / Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins : rationale and design of the ODYSSEY COMBO I and II trials. In: BMC Cardiovascular Disorders. 2014 ; Vol. 14, No. 1. pp. 121.

@article{c57a9479dd5345deac2974ffde30931a,

title = "Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials",

abstract = "Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PCSK9) under investigation for treatment of hypercholesterolemia and reduction of cardiovascular events.",

author = "Colhoun, {Helen M.} and Robinson, {Jennifer G.} and Michel Farnier and Bertrand Cariou and Dirk Blom and Kereiakes, {Dean J.} and Christelle Lorenzato and Robert Pordy and Umesh Chaudhari",

year = "2014",

doi = "10.1186/1471-2261-14-121",

language = "English",

volume = "14",

pages = "121",

journal = "BMC Cardiovascular Disorders",

issn = "1471-2261",

publisher = "Springer Verlag",

number = "1",

}

Colhoun, HM, Robinson, JG, Farnier, M, Cariou, B, Blom, D, Kereiakes, DJ, Lorenzato, C, Pordy, R & Chaudhari, U 2014, 'Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials', BMC Cardiovascular Disorders, vol. 14, no. 1, pp. 121. https://doi.org/10.1186/1471-2261-14-121

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. / Colhoun, Helen M. (Lead / Corresponding author); Robinson, Jennifer G.; Farnier, Michel et al.
In: BMC Cardiovascular Disorders, Vol. 14, No. 1, 2014, p. 121.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins

T2 - rationale and design of the ODYSSEY COMBO I and II trials

AU - Colhoun, Helen M.

AU - Robinson, Jennifer G.

AU - Farnier, Michel

AU - Cariou, Bertrand

AU - Blom, Dirk

AU - Kereiakes, Dean J.

AU - Lorenzato, Christelle

AU - Pordy, Robert

AU - Chaudhari, Umesh

PY - 2014

Y1 - 2014

N2 - Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PCSK9) under investigation for treatment of hypercholesterolemia and reduction of cardiovascular events.

AB - Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PCSK9) under investigation for treatment of hypercholesterolemia and reduction of cardiovascular events.

U2 - 10.1186/1471-2261-14-121

DO - 10.1186/1471-2261-14-121

M3 - Article

C2 - 25240705

SN - 1471-2261

VL - 14

SP - 121

JO - BMC Cardiovascular Disorders

JF - BMC Cardiovascular Disorders

IS - 1

ER -

Colhoun HM, Robinson JG, Farnier M, Cariou B, Blom D, Kereiakes DJ et al. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovascular Disorders. 2014;14(1):121. doi: 10.1186/1471-2261-14-121